Biosidus Announces Promising Interim Results from Phase III Study on Agalsidase Beta for Fabry Disease

BUENOS AIRES, Argentina, April 16, 2025 (Korea Bizwire) – Biosidus, an Argentinean pioneer company in biotechnology research, development, and the production of high-quality biosimilars, has announced encouraging interim results from the Phase III SMILE1 study. After 26 weeks of treatment, the study successfully met its primary endpoint, underscoring the potential of agalsidase beta as a safe and effective biosimilar treatment for Fabry [...]